Pediatric Protocol In Written Agreement Should Be Strictly Followed - FDA
This article was originally published in The Tan Sheet
Executive Summary
NDA sponsors will be expected to adhere precisely to study protocols included in written agreements, FDA's revised guidance on pediatric exclusivity states.
You may also be interested in...
Pediatric study proposals will be prioritized by time of submission, FDA guidance states.
PEDIATRIC DRUG STUDY PROPOSALS WILL BE PRIORITIZED BY TIME OF SUBMISSION and the date of expiry of marketing exclusivity or patent, FDA's June 29 "Qualifying for Pediatric Exclusivity" guidance states. The agency will give top priority review to drugs that lose marketing exclusivity on or before March 31, 1999 if the sponsor submits a proposed pediatric study request by this Aug. 31. The drug must be one of about 490 included in the priority pediatric drug list issued May 20, of which 23 are OTCs ("The Tan Sheet" May 25, p. 12).
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands